Salubris(SZ:002294) Xin Lang Cai Jing·2025-10-29 02:26Core Viewpoint - The stock of Shenzhen Xinlitai Pharmaceutical Co., Ltd. has experienced fluctuations, with a year-to-date increase of 82.91% as of October 29, 2023, despite a recent decline of 2.01% in intraday trading [1][2]. Financial Performance - For the period from January to September 2025, Xinlitai achieved a revenue of 3.241 billion yuan, representing a year-on-year growth of 8.00%, and a net profit attributable to shareholders of 581 million yuan, reflecting a growth of 13.93% [2]. - The company has distributed a total of 7.204 billion yuan in dividends since its A-share listing, with 1.649 billion yuan distributed over the past three years [3]. Stock Market Activity - As of October 29, 2023, Xinlitai's stock price was 55.66 yuan per share, with a market capitalization of 62.051 billion yuan. The trading volume was 48.616 million yuan, with a turnover rate of 0.08% [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on June 17, 2023, where it recorded a net buy of -41.9885 million yuan [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 25,200, with an average of 44,249 circulating shares per shareholder, a decrease of 4.64% from the previous period [2]. - The top circulating shareholders include China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with significant increases in their holdings [3].